Upgrade to SI Premium - Free Trial

Cytokinetics (CYTK) PT Raised to $83 at BofA Securities

May 5, 2026 3:11 PM
BofA Securities analyst Jason Zemansky raised the price target on Cytokinetics (NASDAQ: CYTK) to $83.00 (from $67.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change